<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">761518</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2021.761518</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Antifungal Activity of ToAP2D Peptide Against <italic>Sporothrix globosa</italic>
</article-title>
<alt-title alt-title-type="left-running-head">Yan et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">ToAP2D Against <italic>Sporothrix globosa</italic>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yan</surname>
<given-names>Tianyi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Fuqiu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Jinran</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1157627/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Department of Dermatology, Second Hospital of Jilin University, <addr-line>Changchun</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Department of Dermatology, China-Japan Union Hospital of Jilin University, <addr-line>Changchun</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/517959/overview">Guoming Sun</ext-link>, Hebei University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1463828/overview">Yunfeng Zhao</ext-link>, Ochsner LSU Health, United&#x20;States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1464212/overview">Xianglan Zhang</ext-link>, Yonsei University, South Korea</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Jinran Li, <email>lijr1990@jlu.edu.cn</email>; Feng Chen, <email>chenfengdoctor@jlu.edu.cn</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>761518</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>09</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Yan, Li, Li and Chen.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Yan, Li, Li and Chen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Improving clinical efficacy and reducing treatment time have been the focus of sporotrichosis therapy. Antimicrobial peptides ToAP2A, ToAP2C, and ToAP2D were synthesized on the basis of ToAP2 (AP02759), a peptide derived from the antimicrobial peptide database by the database filtering technology, and their physicochemical characteristics were analyzed. Compared with template peptide ToAP2, the modified peptides had much shorter length, lower molecular weight but significantly greater stability, which in return resulted in increases in the aliphatic index, hydrophilicity, and protein binding ability. Here, we show that the three derived peptides inhibit the growth of <italic>Sporothrix globosa</italic>, among which ToAP2D had the strongest anti-fungal activity. ToAP2D showed good serum stability without acute toxicity. The ToAP2D treatment inhibited the growth of <italic>S. globosa</italic> and enhanced apoptosis, which was evidenced by the upregulation of apoptosis-related protein caspase-3. The scanning electron microscopy analysis revealed deformation and rupture of <italic>S. globosa</italic>. The levels of mitochondrial membrane potential were decreased and that of the reactive oxygen species (ROS) were increased in <italic>S. globosa</italic> upon ToAP2D treatment. Moreover, ToAP2D activated metacaspase. In the <italic>in vivo</italic> study, we further demonstrated that ToAP2D inhibited the <italic>S. globosa</italic> infection of mice footpads, and its efficiency was nearly comparable to itraconazole. In summary, our results suggest that antimicrobial peptide ToAP2D has the potential for sporotrichosis therapy.</p>
</abstract>
<kwd-group>
<kwd>antimicrobial peptide</kwd>
<kwd>design and modification</kwd>
<kwd>apoptosis</kwd>
<kwd>
<italic>Sporothrix globosa</italic>
</kwd>
<kwd>anti-fungal activity</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Jilin Scientific and Technological Development Program<named-content content-type="fundref-id">10.13039/501100013061</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Jilin Province Development and Reform Commission<named-content content-type="fundref-id">10.13039/100015800</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Sporotrichosis is a subcutaneous mycotic infection, which causes localized cutaneous and even severe systemic disseminated infections, and its global incidence increases every year (<xref ref-type="bibr" rid="B9">Etchecopaz et&#x20;al., 2021</xref>). <italic>Sporothrix globosa</italic> is the predominant etiologic agent that brings about sporotrichosis in East Asia, notably in northeast China (<xref ref-type="bibr" rid="B45">Yao et&#x20;al., 2020</xref>). An epidemiologic study found that approximately 1.6 million people die from fungal infections in the world each year (<xref ref-type="bibr" rid="B37">Struyfs et&#x20;al., 2021a</xref>), and a global increase in sporotrichosis incidence occurs every year, especially in the tropical and subtropical regions (<xref ref-type="bibr" rid="B4">Chakrabarti et&#x20;al., 2015</xref>). Current therapies to treat sporotrichosis are very limited, which mainly include antifungal drugs, photodynamic therapy, thermotherapy, cryotherapy, and surgery, and the effects are still far from satisfactory (<xref ref-type="bibr" rid="B15">Honse et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B24">MF Matos et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B35">Soeiro Sampaio et&#x20;al., 2020</xref>). A more efficient treatment for sporotrichosis is greatly desired.</p>
<p>Antimicrobial peptides (AMPs) are commonly found in natural organisms, and they have a wide range of functions, including anti-pathogens (<xref ref-type="bibr" rid="B36">Stariha and McCafferty, 2021</xref>; <xref ref-type="bibr" rid="B5">Chang et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B19">Kim et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B31">Sabia Junior et&#x20;al., 2019</xref>), anti-cancer (<xref ref-type="bibr" rid="B30">Rubin and Qvit, 2020</xref>), and immune regulation (<xref ref-type="bibr" rid="B39">Sun et&#x20;al., 2015</xref>). The current antimicrobial peptide database (<ext-link ext-link-type="uri" xlink:href="http://aps.unmc.edu/AP/main.html">http://aps.unmc.edu/AP/main.html</ext-link>) includes 1,210 types of peptides with antifungal activity. The specific mechanisms of antimicrobial peptides mainly include plasma membrane disruption and non-membranolytic cytotoxicity. The plasma membrane disruption pathway indicates that the positively charged antimicrobial peptides bind to the negatively charged membrane of the pathogens, destroying its integrity, leaking contents, and causing death (<xref ref-type="bibr" rid="B13">Guilhelmelli et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B8">Deslouches and Di, 2017</xref>; <xref ref-type="bibr" rid="B26">Mwangi et&#x20;al., 2019</xref>). In addition, non-membranolytic cytotoxicity is also involved in antimicrobial activity, such as genetic material damage, immune regulation, and apoptosis (<xref ref-type="bibr" rid="B42">Wassing et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B38">Struyfs et&#x20;al., 2021b</xref>). Unlike traditional antibiotics, antimicrobial peptides have many advantages such as quick killing effect and low tendency to induce resistance (<xref ref-type="bibr" rid="B14">Guilhelmelli et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B44">Xu et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B17">Jayawant et&#x20;al., 2021</xref>). However, natural antimicrobial peptides are usually longer peptides with relatively low activity, high cytotoxicity, and strong antigenicity, and these drawbacks limit their applications (<xref ref-type="bibr" rid="B21">Kreling et&#x20;al., 2016</xref>). Hence, modifying and tailoring the structure of AMPs that allow us to circumvent the limits may find more applications.</p>
<p>A previous study showed that scorpion venom&#x2013;derived antimicrobial peptide ToAP2 (AP02759) could inhibit the growth of <italic>Candida albicans</italic> (<xref ref-type="bibr" rid="B14">Guilhelmelli et&#x20;al., 2016</xref>). Moreover, ToAP2 has the characteristics of low hemolytic, low cytotoxic, and remarkable antifungal biofilm activity, suggesting that it had great potentials for the development of new antifungal drugs (<xref ref-type="bibr" rid="B14">Guilhelmelli et&#x20;al., 2016</xref>). As the biological characteristics of <italic>S. globosa</italic> are very similar to <italic>C. albicans</italic>, we then use ToAP2structure as a template, through reasonable molecular design and modification, to study the inhibitory effect of antimicrobial peptides on sporotrichosis.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Materials</title>
<p>Antimicrobial peptides ToAP2A, ToAP2C, and ToAP2D were purchased from Chinapeptides Co. Ltd. (Suzhou, China). The Hoechst 33342&#x2013;propidium iodide (PI) double-staining apoptosis-detection, ROS detection assay, and JC-1 kits were purchased from Beyotime Institute of Biotechnology (Jiangsu, China). The Cas-pACE FITC-VAD-FMK <italic>in situ</italic> marker was acquired from Promega Corporation (Fitchburg, WI, United&#x20;States). All of these reagents were used directly without further treatment. Female BALB/c mice (8&#x2013;10&#xa0;weeks of age; body weight: 16&#x2013;20&#xa0;g) were purchased from Changchun Yisi Experimental Animal Technology Co. (JiLin, China) and used for all <italic>in vivo</italic> experiments.</p>
</sec>
<sec id="s2-2">
<title>Antimicrobial Peptide Bioinformatic Analysis</title>
<p>On the basis of the antimicrobial peptide ToAP2 (AP02759), we designed antimicrobial peptides ToAP2A (GSKLIPGVMKLFSKK), ToAP2B(FFGTLF KLGSKLIPGV), ToAP2C(GAKLIPGVMKLFRKK), ToAP2D (GDKLIPGVMK LFRKK) by intercepting its effective fragments and substituting amino acids. Physical and chemical parameters of the newly designed peptides were analyzed using ExPASy Prot Param. The secondary structures of the peptides were constructed by HNN software of&#x20;NPS@.</p>
</sec>
<sec id="s2-3">
<title>
<italic>S. globosa</italic> Preparation and Culture Conditions</title>
<p>
<italic>S. globosa</italic> was collected from clinical patients diagnosed with cutaneous sporotrichosis at our hospital. All strains were identified as <italic>S. globosa</italic> using mycelial-to-yeast phase conversion culture and molecular identification methods. All isolates were grown on Sabouraud&#x2019;s dextrose agar. After 7&#xa0;days of culture, the fungal colonies were transferred to brainheart infusion broth and incubated in a rotary shaker (150&#xa0;rpm/min) at 37&#xb0;C for another 7&#xa0;days. <italic>S. globosa</italic> was centrifuged and resuspended in PBS and diluted to 1.0 &#xd7; 10<sup>8</sup>&#xa0;cfu/ml.</p>
</sec>
<sec id="s2-4">
<title>Antimicrobial Peptides ToAP2A, ToAP2C, and ToAP2D Against <italic>S. globosa In Vitro</italic>
</title>
<p>The antifungal activity of ToAP2A, ToAP2C, and ToAP2D against <italic>S. globosa</italic> was analyzed using the inhibition zone test. <italic>S. globosa</italic> was collected and diluted to 1.0 &#xd7; 10<sup>8</sup>&#xa0;cfu/ml with a hemocytometer. We then evenly inoculated on brainheart infusion broth agar plates with 50&#xa0;&#xb5;L aliquots of the dilution. Paper disks with 5&#xa0;mm diameter were pasted on the surface of the solid culture medium after high-pressure sterilization. ToAP2A, ToAP2C, and ToAP2D (4/2/1&#xa0;mg/ml) and the control sample (physiological saline with a concentration of 0.9%) were dripped onto the filter paper with 6&#x20;&#xb5;L, respectively, and cultured in 37&#xb0;C for 72&#xa0;h to observe whether there is a zone of inhibition. The diameter of the inhibition zone was measured and recorded with a vernier caliper. The above steps were repeated three times to calculate the average value and standard deviation of the inhibition zone diameter of each sample.</p>
</sec>
<sec id="s2-5">
<title>Minimal Inhibitory Concentration Assay of ToAP2D <italic>In Vitro</italic>
</title>
<p>The minimal inhibitory concentration (MIC) of ToAP2D against <italic>S. globosa</italic> was determined using the microdilution assay. In brief, twofold serial dilutions of ToAP2D were prepared in 96-well polystyrene microplates to a final volume of 100&#xa0;&#xb5;L. Final concentrations of ToAP2D ranged from 5&#xa0;mg/ml to 0.62&#xa0;&#x3bc;g/ml. In each plate, wells were included without peptide as control. Then, 100&#xa0;&#xb5;L of the liquid medium (brainheart infusion broth) was added to each well with a final concentration of 1&#x20;&#xd7; 10<sup>8</sup>&#xa0;cfu/ml for <italic>S. globosa</italic>. The plates were incubated at 37&#xb0;C for 7&#xa0;days. In addition, 20&#xa0;&#xb5;L of culture from each well was inoculated on the brainheart solid medium and cultured in a constant temperature incubator at 37&#xb0;C for 7&#xa0;days to observe the growth of colonies. The MIC was defined as the lowest ToAP2D concentration that completely inhibited visible <italic>S. globosa</italic> growth at the end of the incubation period. The experiments were performed at least three times on separate&#x20;dates.</p>
</sec>
<sec id="s2-6">
<title>Serum Preparation and ToAP2D Serum Stability Assays</title>
<p>The stability of ToAP2D in human serum was analyzed using the inhibition zone test. 5&#xa0;ml of healthy human blood (from the physical examination center of our hospital) was extracted using a sterile syringe, stored at room temperature for 1 h, and then stored at 4&#xb0;C overnight. After 24&#xa0;h, the blood was centrifuged at 1,000&#xa0;rpm/min for 10&#xa0;min, and 50&#xa0;&#xb5;L of serum in the supernatant was gently sucked out with a pipette gun. The serum was diluted with 50&#xa0;&#xb5;L of 0.9% normal saline, and then, the antimicrobial peptide ToAP2D was dissolved in the diluted&#x20;serum.</p>
<p>To determine the stability of ToAP2D in human serum, ToAP2D (final concentration 4&#xa0;mg/ml) was mixed with the diluted serum for 0, 0.5, 1, 2, 4, 6, 8, and 10&#xa0;h at 37&#xb0;C, respectively. In brief, <italic>S. globosa</italic> was inoculated on brainheart infusion broth agar plates, 5.0&#xa0;mm paper disks were placed on top, and 6&#xa0;&#xb5;L aliquots of the serumpeptide mixture were added to the paper disks at each incubation time point. After 24&#xa0;h of incubation, the inhibitory zones against <italic>S. globosa</italic> were measured and recorded.</p>
</sec>
<sec id="s2-7">
<title>ToAP2D Acute Toxicity Analysis</title>
<p>To examine their toxicity, an <italic>in vivo</italic> animal study was performed. The 10 healthy BALB/c mice were randomly divided into ToAP2D group (<italic>n</italic>&#x20;&#x3d; 5) and the control group (<italic>n</italic>&#x20;&#x3d; 5). The mice in the ToAP2D group were injected with ToAP2D through the tail vein at a dose of 60&#xa0;mg/kg, and the control group mice were injected with the same volume of normal saline. After 24&#xa0;h, the major organs (e.g., brain, heart, liver, and kidney) of the mice were excised and fixed in 10% buffered formalin for 1&#xa0;day. The tissues were then embedded in paraffin and sectioned for hematoxylin and eosin (HE) staining.</p>
</sec>
<sec id="s2-8">
<title>
<italic>In Vitro</italic> ToAP2D Treatment Protocol</title>
<p>We inoculated <italic>S. globosa</italic> (1 &#xd7; 10<sup>8</sup>&#xa0;cfu/ml) on the brain heart solid culture dish evenly in the clean bench. After 24&#xa0;h, the 12 culture dishes were randomly divided into control group (n &#x3d; 6) and the study group (<italic>n</italic>&#x20;&#x3d; 6). The <italic>S. globosa</italic> control group was not treated, while the study group was treated with ToAP2D (4&#xa0;mg/ml). The antifungal capacities of antibacterial peptide ToAP2D against <italic>S. globosa in&#x20;vitro</italic> were examined 24&#xa0;h&#x20;later.</p>
</sec>
<sec id="s2-9">
<title>Observation of <italic>S. globosa</italic> Morphology After ToAP2D Treatment</title>
<p>
<italic>S. globosa</italic> in both groups was cultured in 24-well tissue culture plates with cell slide for 4&#xa0;h. After removing the supernatant and washing each well with PBS three times, we fixed both strains with 2.5% glutaraldehyde for 2&#xa0;h. After fixation, disks were rinsed three times with PBS and dehydrated in an ethanol series (30, 50, 70, 80, 90% for 7&#xa0;min each, 100% for 10&#xa0;min). Disks were dried at conventional critical point and vacuum sputter gold coated. The morphology of <italic>S. globosa</italic> was observed using a scanning electron microscope (SEM) (Hitachi, Tokyo, Japan).</p>
</sec>
<sec id="s2-10">
<title>Cell Apoptosis and Necrosis After ToAP2D Treatment</title>
<p>Cell apoptosis and necrosis were analyzed using the Hoechst 33342&#x2013;propidium iodide (PI) double-staining apoptosis-detection kit (Beyotime Institute of Biotechnology, Jiangsu, China). The strains of the study and control groups were centrifuged at 3,000&#xa0;rpm for 5&#xa0;min and then resuspended at 800&#xa0;&#xb5;L staining buffer. The strain solution was rinsed twice with PBS and then diluted to 1&#x20;&#xd7; 10<sup>6</sup>&#xa0;cfu/ml with a hemocytometer. 5&#xa0;&#xb5;L of Hoechst 33342 and 5&#xa0;&#xb5;L of PI were incubated into the solution and mixed according to the manufacturer&#x2019;s instructions. The solution was washed with PBS once after ice bath for 30&#xa0;min. The smears were observed under a laser scanning confocal microscope (Zeiss LSM 780, German).</p>
</sec>
<sec id="s2-11">
<title>ROS and Mitochondrial Membrane Potential Detection After ToAP2D Treatment</title>
<p>ROS and mitochondrial membrane potential levels were measured using an ROS detection assay kit and a JC-1 kit (Beyotime Institute of Biotechnology, Jiangsu, China), respectively. The strains of the study and control groups were diluted to 1&#x20;&#xd7; 10<sup>8</sup>&#xa0;cfu/ml.</p>
<p>To detect the ROS level change of <italic>S. globosa</italic> after laser irradiation, the strains in the study and control groups were incubated in dichlorodihydrofluorescein diacetate (DCFH-DA) (10&#xa0;&#xb5;M) for 20&#xa0;min at 37&#xb0;C. After being washed three times with YPD, <italic>S. globosa</italic> was treated with an active oxygen positive control reagent, an experimental group reagent, and a control group reagent, respectively. After 20&#xa0;min, the fluorescence intensity was monitored by the microplate fluorescence reader. The ROS level was calculated as the manufacturer&#x2019;s instructions.</p>
<p>To detect the changes in mitochondrial membrane potential of <italic>S. globosa</italic> after ToAP2D treatment, strains in the study and control groups were stained with JC-1. After being washed three times and resuspended in PBS, <italic>S. globosa</italic> in the study and control groups was added with JC-1 (5&#xa0;&#x3bc;M) and mixed incubation was performed at 37&#xb0;C for 20&#xa0;min. The absorbance was measured with the microplate fluorescence reader at the excitation wavelength of 490&#xa0;nm and emissions at 530&#xa0;nm.</p>
</sec>
<sec id="s2-12">
<title>Metacaspase Detection After ToAP2D Treatment</title>
<p>Metacaspases activity was measured using the Cas-pACE FITC-VAD-FMK <italic>in situ</italic> marker (Promega, Fitchburg, WI, United&#x20;States). The strains of the study and control groups were centrifuged at 3,000&#xa0;rpm for 5&#xa0;min and diluted to 1&#x20;&#xd7; 10<sup>6</sup>&#xa0;cfu/ml. <italic>S. globosa</italic> was washed with PBS once before staining with 10&#xa0;&#xb5;M CaspACE FITC-VAD-FMK. After 20&#xa0;min of incubation at 37&#xb0;C, <italic>S. globosa</italic> was washed twice with PBS, and the fluorescence absorption was detected by flow cytometry. The excitation light wavelength and the emission light wavelength were set to 494 and 518&#xa0;nm, respectively.</p>
</sec>
<sec id="s2-13">
<title>Animals Treatment Protocol</title>
<p>The animal protocol was approved by the Institutional Ethics Committee for Animal Use in Research, and our animal care followed Animal Care guidelines of the Jilin University. Mice were randomly divided into study group (<italic>n</italic>&#x20;&#x3d; 51) and the healthy control (HC) group (<italic>n</italic>&#x20;&#x3d; 6). Mice in the study group were injected with 0.05&#xa0;ml <italic>S. globosa</italic> suspension (1 &#xd7; 10<sup>8</sup>&#xa0;cfu/ml) on their footpads after alcohol cotton ball sterilization. The condition of the skin was monitored daily. On Day 10, we proved that the mouse model was successfully established evidenced by mice histopathology changes (<italic>n</italic>&#x20;&#x3d; 3) in the study group. After that, CO<sub>2</sub> lattice laser was used to promote ToAP2D absorption, and the mice of the study group were further divided into infection group (<italic>n</italic>&#x20;&#x3d; 12), laser group (<italic>n</italic>&#x20;&#x3d; 12), laser &#x2b; ToAP2D group (<italic>n</italic>&#x20;&#x3d; 12), and itraconazole group (<italic>n</italic>&#x20;&#x3d; 12), and the antifungal treatments were given subsequently.</p>
<p>In the laser group, the injection feet were subjected to CO<sub>2</sub> lattice laser 10,600&#xa0;nm irradiation at room temperature with an irradiation energy density of 120&#xa0;mJ/mm<sup>2</sup>. The laser scanning area was 15&#xa0;mm &#xd7; 15&#xa0;mm with a lattice density of 0.3&#xa0;mm and 25.0% coverage rate. The laser treatment was administered every 3&#xa0;days on Day 10, 14, 18, and 22. In the laser &#x2b; ToAP2D group, mice were subjected to CO<sub>2</sub> lattice laser irradiation with the same parameters in the laser group to assist the absorption of ToAP2D. Almost immediately after laser irradiation, the antibacterial peptide ToAP2D (4&#xa0;mg/ml, diluted with 0.9% normal saline) was repeatedly rolled onto the laser-irradiated part of the footpad, until it was completely absorbed every day. In the itraconazole group, mice were gavaged with itraconazole at a dose of 60&#xa0;mg/kg daily. The size of the footpads of mice was measured every 3&#xa0;days and analyzed using <ext-link ext-link-type="uri" xlink:href="https://www.sogou.com/link?url=hedJjaC291NNchcL_01ZXPJRao-Z2kCCMdBPcC-xE5KyndbgJnzmoCHmfGkNvdZG">Photoshop</ext-link>. On Day 18 and 26, six mice in each group were sacrificed, and their feet tissues were collected for further skin histology and immunohistochemistry studies.</p>
</sec>
<sec id="s2-14">
<title>Histology</title>
<p>The fungal inoculation sites of mice skin were isolated and fixed with 10% buffered formalin. Samples were dehydrated, paraffin-embedded, and sliced into 5&#xa0;&#xb5;m sections. Then, they were stained with HE to observe the inflammation in the tissue. The software ImageJ was used to quantify the percentage area of inflammatory cells on Day 18 and Day 26, respectively.</p>
<p>The expression of caspase-3 was detected using immunohistochemistry to evaluate the apoptosis in mice footpad tissues after different treatments. In brief, paraffin-embedded sections of mice footpad tissue in different groups were dewaxed and gradually rehydrated before being immersed in an EDTA solution (pH 9.0). After 150&#xa0;s of heating at 120&#xb0;C, the antigen was slowly cooled to room temperature. After fixation, immunostaining blocking solution was used to block and incubate with primary antibody at 4&#xb0;C overnight. The caspase-3 rabbit polyclonal antibody (AF0081, Beyotime Biotechnology; 1:100) was added. After washing with PBS, the tissue sections were incubated with an HRP-conjugated secondary antibody for 20&#xa0;min at 37&#xb0;C and visualized with diaminobenzidine (DAB), followed by counterstaining with hematoxylin, hydrochloric acid ethanol differentiation, phosphate buffer solution back blue, gradient ethanol dehydration, xylene transparent, and neutral gum seal. The relative expression of apoptotic factor caspase-3 was assessed by average optic density (AOD) obtained from ImageJ, AOD &#x3d; integrated optical density (IOD)/area.</p>
</sec>
<sec id="s2-15">
<title>Statistical Analysis</title>
<p>Graphpad Prism 7.0 software (Graphpad Software, La, Jolla, CA, United&#x20;States) was used to conduct the statistical analysis and figure production. Data were summarized as median and range for non-normal distribution data or mean&#x20;&#xb1; standard deviation (SD) for normally distributed data. The quantitative analysis of caspase-3 was performed to assess the average optic density (AOD) obtained from ImageJ.&#x20;Statistical significance was determined using the one-way analysis of variance (ANOVA), Mann&#x2013;Whitney <italic>U</italic> test, or Student&#x2019;s t-test. All <italic>in&#x20;vitro</italic> study experiments were performed in triplicate. <italic>p</italic>&#x20;&#x3c; 0.05 was considered to be statistically significant.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<sec id="s3-1">
<title>Peptide Design and Functional Screening</title>
<p>The sequences and bioinformatic characterization of the ToAP2 and its derived peptides ToAP2A, ToAP2B, ToAP2C, and ToAP2D are presented in <xref ref-type="table" rid="T1">Table&#x20;1</xref>,&#x20;<xref ref-type="table" rid="T2">2</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The comparison of ToAP2 amino acid sequences and derived peptides.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Peptide</th>
<th align="center">Sequence</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">ToAP2</td>
<td align="left">FFGTLFKLGSKLIPGVMKLFSKKKER</td>
</tr>
<tr>
<td align="left">ToAP2A</td>
<td align="left">GSKLIPGVMKLFSKK</td>
</tr>
<tr>
<td align="left">ToAP2B</td>
<td align="left">FFGTLFKLGSKLIPGV</td>
</tr>
<tr>
<td align="left">ToAP2C</td>
<td align="left">GAKLIPGVMKLFRKK</td>
</tr>
<tr>
<td align="left">ToAP2D</td>
<td align="left">GDKLIPGVMKLFRKK</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>The comparison of physical and chemical properties of ToAP2 and its derived peptides.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Peptide</th>
<th align="center">Molecular weight (Da)</th>
<th align="center">Sequence length</th>
<th align="center">alpha-Helix(%)</th>
<th align="center">PI</th>
<th align="center">Net charge</th>
<th align="center">GRAVY</th>
<th align="center">Total hydrophobic ratio (%)</th>
<th align="center">Aliphatic index</th>
<th align="center">Instability index</th>
<th align="center">Boman index (kcal/mol)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">ToAP2</td>
<td align="char" char=".">3,000.73</td>
<td align="char" char=".">26</td>
<td align="char" char=".">69.23</td>
<td align="char" char=".">10.68</td>
<td align="char" char=".">&#x2b;6</td>
<td align="char" char=".">0.019</td>
<td align="char" char=".">42</td>
<td align="char" char=".">86.15</td>
<td align="char" char=".">&#x2212;10.33</td>
<td align="char" char=".">0.66</td>
</tr>
<tr>
<td align="left">ToAP2A</td>
<td align="char" char=".">1,633.07</td>
<td align="char" char=".">15</td>
<td align="char" char=".">60.00</td>
<td align="char" char=".">10.48</td>
<td align="char" char=".">&#x2b;4</td>
<td align="char" char=".">0.093</td>
<td align="char" char=".">40</td>
<td align="char" char=".">97.33</td>
<td align="char" char=".">&#x2212;3.91</td>
<td align="char" char=".">0.18</td>
</tr>
<tr>
<td align="left">ToAP2B</td>
<td align="char" char=".">1724.12</td>
<td align="char" char=".">16</td>
<td align="char" char=".">37.50</td>
<td align="char" char=".">10.00</td>
<td align="char" char=".">&#x2b;2</td>
<td align="char" char=".">1.025</td>
<td align="char" char=".">50</td>
<td align="char" char=".">115.62</td>
<td align="char" char=".">&#x2212;17.74</td>
<td align="char" char=".">-1.15</td>
</tr>
<tr>
<td align="left">ToAP2C</td>
<td align="char" char=".">1,686.18</td>
<td align="char" char=".">15</td>
<td align="char" char=".">66.67</td>
<td align="char" char=".">11.33</td>
<td align="char" char=".">&#x2b;5</td>
<td align="char" char=".">0.02</td>
<td align="char" char=".">46</td>
<td align="char" char=".">104</td>
<td align="char" char=".">&#x2212;9.57</td>
<td align="char" char=".">0.62</td>
</tr>
<tr>
<td align="left">ToAP2D</td>
<td align="char" char=".">1730.19</td>
<td align="char" char=".">15</td>
<td align="char" char=".">66.67</td>
<td align="char" char=".">10.46</td>
<td align="char" char=".">&#x2b;4</td>
<td align="char" char=".">-0.333</td>
<td align="char" char=".">40</td>
<td align="char" char=".">97.33</td>
<td align="char" char=".">&#x2212;9.57</td>
<td align="char" char=".">1.32</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>A previous study reported that antimicrobial peptide ToAP2 (AP02759), a 26-amino acid peptide, showed high antifungal and antifungal biofilm activity but low hemolytic and cytotoxic activity, indicating that this peptide has great potential for the development of new antifungal drugs (<xref ref-type="bibr" rid="B14">Guilhelmelli et&#x20;al., 2016</xref>). Based on ToAP2, a series of peptides were designed by incorporating effective fragments and amino acid substitutions.</p>
<p>Modifying the antibacterial peptide structure, such as sequence length and special amino acids, can improve its antifungal activity and reduce toxicity (<xref ref-type="bibr" rid="B23">Lima et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B33">Schafer et&#x20;al., 2021</xref>). To test the hypothesis, we first designed ToAP2A and ToAP2B by integrating effective fragments. The bioinformatic characterization data indicated that the sequence length and molecular weight of ToAP2A and ToAP2B were much shorter than that of ToAP2, while the hydropathic and aliphatic index increased. Meanwhile, ToAP2A exhibited enhanced capacity in alpha-helix, instability index, and protein binding ability than ToAP2B. Collectively, ToAP2A has superior properties than ToAP2B and ToAP2.</p>
<p>ToAP2A was used for further modification through amino acid substitution. ToAP2C was first designed by substituting Ser-2/14 residues with Ala-2 and Arg-14. Though ToAP2C exhibited improvements in the positive net charge, alpha-helix, aliphatic index, and protein binding ability, ToAP2A displayed higher hydrophilicity and stability. We further investigated the effect of Ser substitution with Asp-2 and Arg-14 on the property of ToAP2A derivative. The resulting peptide ToAP2D showed better performance in alpha-helix and protein binding ability than ToAP2A.</p>
<p>Taken together, all these results indicated that the properties of ToAP2A, ToAP2C, and ToAP2D are improved compared with ToAP2B and ToAP2, especially in molecular weight, sequence length, and stability.</p>
</sec>
<sec id="s3-2">
<title>Antifungal Activity, Serum Stability, and Acute Toxicity Assays of Antimicrobial Peptides</title>
<p>Antimicrobial peptides ToAP2A, ToAP2C, and ToAP2D were synthesized, and their purities (&#x3e;95%) were determined using reversed-phase high-performance liquid chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS) (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref> and Fig. S1&#x2013;S4).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Synthesized ToAP2D purity was determined using reversed-phase high-performance liquid chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS). <bold>(A)</bold> RP-HPLC analysis <bold>(B)</bold> ESI-MS analysis.</p>
</caption>
<graphic xlink:href="fbioe-09-761518-g001.tif"/>
</fig>
<p>The inhibition zone test was employed to analyze the ToAP2D antifungal activities (<xref ref-type="bibr" rid="B46">Zhang et&#x20;al., 2021</xref>). The results showed that three peptides had no inhibition zone at the concentration of 1&#xa0;mg/ml. When the concentration increased to 2&#xa0;mg/ml and 4&#xa0;mg/ml, they both showed antifungal activities against <italic>S. globosa</italic>, and the noticeable inhibition zone diameter was at 4&#xa0;mg/ml. At the same concentration (4&#xa0;mg/ml), the inhibition zone average diameter of ToAP2D (11.56&#x20;&#xb1; 0.36&#xa0;mm) was significantly greater than that of ToAP2A (9.23&#x20;&#xb1; 0.34&#xa0;mm) and ToAP2C (8.12&#x20;&#xb1; 0.33&#xa0;mm), suggesting that ToAP2D has the strongest antifungal activity against <italic>S. globosa</italic> (<xref ref-type="table" rid="T3">Table&#x20;3</xref>). We further determined that the minimal inhibitory concentration (MIC) of the ToAP2D against <italic>S. globosa</italic> by the microdilution assay was 156.25&#xa0;&#x3bc;g/ml.</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Antibacterial diameter of antimicrobial peptides <italic>in&#x20;vitro</italic>.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="3" align="left">group</th>
<th colspan="3" align="center">concentration (mg/ml)</th>
</tr>
<tr>
<th align="center">4</th>
<th align="center">2</th>
<th align="center">1</th>
</tr>
<tr>
<th colspan="3" align="center">Inhibition zone (mm) mean&#x20;&#xb1; standard deviation (SD)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">ToAP2A</td>
<td align="char" char="plusmn">9.23&#x20;&#xb1; 0.34<xref ref-type="table-fn" rid="Tfn3">
<sup>&#x2a;&#x2a;&#x2a;</sup>
</xref>
</td>
<td align="char" char="plusmn">6.59&#x20;&#xb1; 0.34<xref ref-type="table-fn" rid="Tfn3">
<sup>&#x2a;&#x2a;&#x2a;</sup>
</xref>
</td>
<td align="char" char="plusmn">5.00&#x20;&#xb1; 0.00</td>
</tr>
<tr>
<td align="left">ToAP2C</td>
<td align="char" char="plusmn">8.12&#x20;&#xb1; 0.33<xref ref-type="table-fn" rid="Tfn3">
<sup>&#x2a;&#x2a;&#x2a;</sup>
</xref>
</td>
<td align="char" char="plusmn">6.37&#x20;&#xb1; 0.27<xref ref-type="table-fn" rid="Tfn3">
<sup>&#x2a;&#x2a;&#x2a;</sup>
</xref>
</td>
<td align="char" char="plusmn">5.00&#x20;&#xb1; 0.00</td>
</tr>
<tr>
<td align="left">ToAP2D</td>
<td align="char" char="plusmn">11.56&#x20;&#xb1; 0.36<xref ref-type="table-fn" rid="Tfn3">
<sup>&#x2a;&#x2a;&#x2a;</sup>
</xref>
</td>
<td align="char" char="plusmn">6.86&#x20;&#xb1; 0.25<xref ref-type="table-fn" rid="Tfn3">
<sup>&#x2a;&#x2a;&#x2a;</sup>
</xref>
</td>
<td align="char" char="plusmn">5.00&#x20;&#xb1; 0.00</td>
</tr>
<tr>
<td align="left">control sample</td>
<td align="char" char="plusmn">5.00&#x20;&#xb1; 0.00</td>
<td align="char" char="plusmn">5.00&#x20;&#xb1; 0.00</td>
<td align="char" char="plusmn">5.00&#x20;&#xb1; 0.00</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Normally distributed data are shown as the mean&#x20;&#xb1; SD.</p>
</fn>
<fn id="Tfn1">
<label>&#x2a;</label>
<p>mean compared to control sample, <italic>p</italic>&#x20;&#x3c; 0.05.</p>
</fn>
<fn id="Tfn2">
<label>&#x2a;&#x2a;</label>
<p>mean compared to control sample, <italic>p</italic>&#x20;&#x3c; 0.01.</p>
</fn>
<fn id="Tfn3">
<label>&#x2a;&#x2a;&#x2a;</label>
<p>mean compared to control sample, <italic>p</italic>&#x20;&#x3c; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The serum stability of the drug determines whether it can be administered intravenously (<xref ref-type="bibr" rid="B26">Mwangi et&#x20;al., 2019</xref>). To examine its administration potential, we tested the stability of ToAP2D in human serum. After 10&#xa0;h of incubation in serum, ToAP2D (4&#xa0;mg/ml) showed that its antifungal activity against <italic>S. globosa</italic> was comparable to the original drug (&#x3e;90%). Given that the ToAP2D sequence only contains 15 amino acid residues, it is difficult for ToAP2D to be inactivated by the enzymes in serum. The results suggested that the antibacterial peptide ToAP2D is stable in serum, which may lay a good foundation for the development of anti-bacterial drugs. Additionally, the acute toxicity for the ToAP2D was evaluated by HE staining of the main organs of mice (<xref ref-type="bibr" rid="B22">Li et&#x20;al., 2020</xref>). As shown in <xref ref-type="fig" rid="F2">Figure&#x20;2</xref>, no ultrastructural changes were observed in all main organs of the control and ToAP2D treated groups, which suggested that ToAP2D has no acute toxicity.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>HE staining of mice major organs (brain, heart, liver, spleen, lung, and kidney) in the ToAP2D treatment and control group. The scale bar &#x3d; 200&#xa0;&#x3bc;m.</p>
</caption>
<graphic xlink:href="fbioe-09-761518-g002.tif"/>
</fig>
<p>Overall, these results indicated that the ToAP2D has great potential for the treatment of <italic>S. globosa</italic> infection with serum stability and no acute toxicity.</p>
</sec>
<sec id="s3-3">
<title>
<italic>S. globosa</italic> Morphological Changes After ToAP2D Treatment <italic>In Vitro</italic>
</title>
<p>Antimicrobial peptides often induce fungal morphology and structure changes (<xref ref-type="bibr" rid="B40">Vieira Bard et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B20">Kong et&#x20;al., 2019</xref>). To assess the possible mechanism of ToAP2D action, the morphology of <italic>S. globosa</italic> was observed using a scanning electron microscope (SEM). <italic>S. globosa</italic> showed normal morphology in the control group, which has a regular oval shape, complete and smooth surface, clear borders with no wrinkles (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>). However, we found that the <italic>S. globosa</italic> morphology changed significantly after ToAP2D treatment. There are many granular or vesicle-like structures that appeared on the surface, and some areas showed irregular shapes (e.g., depressions, holes, and leakage of contents) (<xref ref-type="fig" rid="F3">Figures 3C&#x2013;F</xref>). This indicated that ToAP2D treatment may destroy the cell wall and membrane of <italic>S. globosa</italic>, thereby selectively destroying its permeability, reducing the intracellular osmotic pressure, causing a large amount of cytoplasm to leak out, and promoting its death. In the meantime, these results indicated that ToAP2D might have a necrosis effect on <italic>S. globosa</italic>. Additionally, histology research showed that morphological changes, including cell shrinkage, nuclear karyorrhexis, and plasma membrane blebbing phenomenon, are also involved in the process of apoptosis (<xref ref-type="bibr" rid="B32">Saikumar and Kar, 2008</xref>) (<xref ref-type="bibr" rid="B7">Coleman and Olson, 2002</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effect of ToAP2D treatment on morphological changes of <italic>S. globosa</italic> was observed by SEM <bold>(A,B)</bold> <italic>S. globosa</italic> in the control group was normal morphology. <bold>(C&#x2013;F)</bold> <italic>S. globosa</italic> morphological changes after ToAP2D treatment. The scale bars in <bold>(A)</bold>, <bold>(C)</bold>, and <bold>(E)</bold> represent 10&#xa0;&#x3bc;m, and those in <bold>(B)</bold>, <bold>(D)</bold>, and <bold>(F)</bold> represent 5&#xa0;&#x3bc;m.</p>
</caption>
<graphic xlink:href="fbioe-09-761518-g003.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>
<italic>S. globosa</italic> Apoptosis After ToAP2D Treatment <italic>In Vitro</italic>
</title>
<p>Apoptosis and necrosis are the two major forms of cell death, which are crucial for maintaining the body development and removing abnormal cells (<xref ref-type="bibr" rid="B18">Ju et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B29">Riwaldt et&#x20;al., 2021</xref>). To investigate the effect of ToAP2D on apoptosis and necrosis, a Hoechst/PI double staining was performed. We observed that there was only weak blue fluorescence and red fluorescence in the control group, indicating that <italic>S. globosa</italic> was in a normal state. However, strong blue fluorescence and red fluorescence (Hoechst&#x2b;/PI&#x2b;) were observed in the laser irradiation group (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>), suggesting that ToAP2D treatment significantly promoted the apoptosis and necrosis of <italic>S. globosa</italic>.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Effect of ToAP2D treatment on apoptosis of <italic>S. globosa</italic>. <bold>(A)</bold> Laser scanning confocal microscope was used to observe the apoptosis and necrosis effect of ToAP2D treatment. The scale bar &#x3d; 20&#xa0;&#x3bc;m. <bold>(B)</bold> Flow cytometry was used to detect the ROS accumulation. <bold>(C)</bold> Flow cytometry was used to detect the mitochondrial membrane potential. <bold>(D)</bold> Flow cytometry was used to detect the metacaspase activation. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 indicate statistical significance.</p>
</caption>
<graphic xlink:href="fbioe-09-761518-g004.tif"/>
</fig>
<p>Great efforts have been made to explore the mechanism of <italic>S. globosa</italic> apoptosis. ROS is an important regulator of cell apoptosis, which can damage DNA and affect cell cycle process (<xref ref-type="bibr" rid="B16">Ikner and Shiozaki, 2005</xref>). After ToAP2D treatment, we found that the ROS accumulation was significantly elevated (40.84&#x20;&#xb1; 5.69% versus 4.65&#x20;&#xb1; 1.00%; <italic>p</italic>&#x20;&#x3d; 0.004) (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>), indicating that ROS-mediated apoptosis pathway was activated.</p>
<p>The decrease in mitochondrial membrane potential signifies cell apoptosis (<xref ref-type="bibr" rid="B12">Guaragnella et&#x20;al., 2012</xref>). A recent study revealed that ROS promoted the irreversible over-opening of mitochondrial permeability transition pores, leading to the decrease in mitochondrial membrane potential (<xref ref-type="bibr" rid="B6">Cho and Lee, 2011</xref>). We thereby investigated the mitochondrial membrane potential between ToAP2D and control groups. Our results showed that ToAP2D treatment reduced the mitochondrial membrane potential (4.30&#x20;&#xb1; 1.29 versus 26.73&#x20;&#xb1; 8.58; <italic>p</italic>&#x20;&#x3d; 0.004) (<xref ref-type="fig" rid="F4">Figure&#x20;4C</xref>), indicating that ToAP2D caused mitochondrial dysfunction.</p>
<p>Metacaspases are orthologues of caspases, which are crucial mediators of apoptosis in fungi and plants. ROS generation can induce caspase-dependent apoptosis (<xref ref-type="bibr" rid="B25">Madeo et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B28">Qi et&#x20;al., 2019</xref>). After ToAP2D treatment, the metacaspase activation of the study and control groups reached 62.05&#x20;&#xb1; 4.15% and 20.73&#x20;&#xb1; 3.05%, respectively (<italic>p</italic>&#x20;&#x3c; 0.001) (<xref ref-type="fig" rid="F4">Figure&#x20;4D</xref>).</p>
<p>Taken together, these results indicated that the ToAP2D treatment resulted in dysfunctional mitochondria and ROS accumulation, and activated the caspase-dependent apoptosis pathway, which triggered <italic>S. globosa</italic> apoptosis.</p>
</sec>
<sec id="s3-5">
<title>
<italic>In Vivo</italic> Skin Infection</title>
<p>CO<sub>2</sub> lattice laser has strong penetrability, which can precisely control the depth of skin penetration and punctate exfoliation (<xref ref-type="bibr" rid="B43">Wenande et&#x20;al., 2017</xref>). Additionally, CO<sub>2</sub> laser surgery is less invasive and causes reduced trauma and pain (<xref ref-type="bibr" rid="B2">Artzi et&#x20;al., 2019</xref>). Recent studies indicated that its thermal effect can inhibit fungi, initiate local immune responses, and assist the absorption of drugs (<xref ref-type="bibr" rid="B27">Orringer et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B34">Sobhi et&#x20;al., 2020</xref>). In our study, we investigated the efficacy and mechanism of ToAP2D against <italic>S. globosa</italic>, and CO<sub>2</sub> lattice laser was used as a way to promote its absorption. Itraconazole is the first-line antifungal agent for sporotrichosis (<xref ref-type="bibr" rid="B10">Garc&#xed;a A. Carnero et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B1">Abbotsford et&#x20;al., 2021</xref>), and it was used to evaluate the ToAP2D anti-fungal activity.</p>
<p>The footpad sizes of the mice were measured on Day 14, 18, 22, and 26 after <italic>S. globosa</italic> injection (<xref ref-type="table" rid="T4">Table&#x20;4</xref>), respectively. The size of mouse skin lesion area was 10.83&#x20;&#xb1; 0.84&#xa0;mm<sup>2</sup> in the HC group (<xref ref-type="fig" rid="F5">Figure&#x20;5A</xref>). The mouse footpads after laser and laser &#x2b; ToAP2D treatment are distinct from the healthy one (<xref ref-type="fig" rid="F5">Figures 5B,C</xref>). The size of footpads in laser &#x2b; ToAP2D and itraconazole groups almost became normal on Day 26, which were both faster than mice in the infection and laser groups (<xref ref-type="fig" rid="F5">Figure&#x20;5D</xref>). From Day 14 to Day 26, a significant size decrease in mouse footpads was observed in all treatment group compared with the infection group (<xref ref-type="fig" rid="F5">Figure&#x20;5E</xref>), while the treatment efficiency in the laser &#x2b; ToAP2D group was better than that of the laser-only group (<xref ref-type="fig" rid="F5">Figure&#x20;5F</xref>). Meanwhile, no significant difference was observed between the laser &#x2b; ToAP2D and itraconazole groups (<xref ref-type="fig" rid="F5">Figure&#x20;5G</xref>), suggesting that their anti-fungal effects were almost the&#x20;same.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>The mice foot skin lesion area analysis.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="left">Parameters</th>
<th rowspan="2" align="center">Study group</th>
<th align="center">Day14</th>
<th align="center">Day18</th>
<th align="center">Day22</th>
<th align="center">Day26</th>
</tr>
<tr>
<th align="center">(n&#x20;&#x3d;&#x20;6)</th>
<th align="center">(n&#x20;&#x3d;&#x20;6)</th>
<th align="center">(n&#x20;&#x3d;&#x20;6)</th>
<th align="center">(n&#x20;&#x3d;&#x20;6)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="4" align="left">Skin lesion area (mm<sup>2</sup>)</td>
<td align="left">Infection group</td>
<td align="char" char="plusmn">43.99&#x20;&#xb1; 5.56<xref ref-type="table-fn" rid="Tfn6">&#x2a;&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">34.19&#x20;&#xb1; 3.53<xref ref-type="table-fn" rid="Tfn4">&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">28.77&#x20;&#xb1; 2.61<xref ref-type="table-fn" rid="Tfn4">&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">24.48&#x20;&#xb1; 2.90<xref ref-type="table-fn" rid="Tfn6">&#x2a;&#x2a;&#x2a;</xref>
</td>
</tr>
<tr>
<td align="left">Laser group</td>
<td align="char" char="plusmn">37.91&#x20;&#xb1; 3.50<xref ref-type="table-fn" rid="Tfn4">&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">29.65&#x20;&#xb1; 1.54<xref ref-type="table-fn" rid="Tfn6">&#x2a;&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">23.48&#x20;&#xb1; 3.00<xref ref-type="table-fn" rid="Tfn4">&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">19.81&#x20;&#xb1; 2.39<xref ref-type="table-fn" rid="Tfn6">&#x2a;&#x2a;&#x2a;</xref>
</td>
</tr>
<tr>
<td align="left">Laser &#x2b; ToAP2D group</td>
<td align="char" char="plusmn">28.71&#x20;&#xb1; 1.66<xref ref-type="table-fn" rid="Tfn6">&#x2a;&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">21.49&#x20;&#xb1; 1.03<xref ref-type="table-fn" rid="Tfn6">&#x2a;&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">15.62&#x20;&#xb1; 2.73<xref ref-type="table-fn" rid="Tfn4">&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">11.81&#x20;&#xb1; 1.02</td>
</tr>
<tr>
<td align="left">Itraconazole group</td>
<td align="char" char="plusmn">27.82&#x20;&#xb1; 2.84<xref ref-type="table-fn" rid="Tfn4">&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">21.47&#x20;&#xb1; 0.92<xref ref-type="table-fn" rid="Tfn6">&#x2a;&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">14.94&#x20;&#xb1; 2.93<xref ref-type="table-fn" rid="Tfn4">&#x2a;&#x2a;</xref>
</td>
<td align="char" char="plusmn">11.81&#x20;&#xb1; 0.85</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Normally distributed data are shown as the mean&#x20;&#xb1; SD.</p>
</fn>
<fn id="Tfn4">
<label>&#x2a;</label>
<p>mean compared to HC, <italic>p</italic>&#x20;&#x3c; 0.05.</p>
</fn>
<fn id="Tfn5">
<label>&#x2a;&#x2a;</label>
<p>mean compared to HC, <italic>p</italic>&#x20;&#x3c; 0.01.</p>
</fn>
<fn id="Tfn6">
<label>&#x2a;&#x2a;&#x2a;</label>
<p>mean compared to HC, <italic>p</italic>&#x20;&#x3c; 0.001.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>The mice skin lesion area comparison after different treatments. <bold>(A)</bold> HC group. <bold>(B)</bold> Laser treatment. <bold>(C)</bold> Laser &#x2b; ToAP2D treatment. <bold>(D)</bold> Compared with the HC group, the footpads&#x2019; size after different treatments from Day14 to 26. <bold>(E)</bold> Compared with the infection group, the footpads&#x2019; size in the laser, laser &#x2b; ToAP2D, and itraconazole group from Day14 to 26. <bold>(F)</bold> Compared with the laser group, the footpads&#x2019; size in laser &#x2b; ToAP2D group from Day14 to 26&#x20;<bold>(G)</bold> Analysis on the trend of the skin lesion area of all groups mice followed up time from Day14 to 26. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 indicate statistical significance.</p>
</caption>
<graphic xlink:href="fbioe-09-761518-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Histopathology and Immunohistochemistry (IHC)</title>
<p>Recent studies revealed that inflammation is closely correlated with the host resistance to sporotrichosis (<xref ref-type="bibr" rid="B3">Batista-Duharte et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B11">Garc&#xed;a-Lozano L. C. et&#x20;al., 2018</xref>). Histopathological analysis is a common method to evaluate the inflammatory response, which was used in this study to assess the ToAP2D treatment efficacy. The normal histopathology of the mice is shown in <xref ref-type="fig" rid="F6">Figure&#x20;6A</xref>. After 10&#xa0;days of infection, three mice in the study group were randomly taken for histopathological examination. We observed suppurative inflammation with epithelioid cells, mononuclear cells, and neutrophils formation, confirming that the <italic>S. globosa</italic> infection mouse model was established successfully (<xref ref-type="fig" rid="F6">Figure&#x20;6B</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>The mice histopathology and IHC comparison after different treatments. We compared the histopathological changes and caspase-3 expression of mice skin tissues on Day18 and 26. <bold>(A)</bold> HC group. <bold>(B)</bold> Study group on Day 10 (red arrow: epithelioid cell, green arrow: mononuclear cell, blue arrow: neutrophil). <bold>(C)</bold> Histopathological changes of mice skin tissues after different treatments on Day 18 and 26. <bold>(D)</bold> Compared with HC, the percentage area of inflammatory cells in different treatment groups on Day 18 and 26, respectively. <bold>(E&#x2013;F)</bold> Compared with HC, the IHC expression of caspase-3 in different treatment groups on Day 18 and 26, respectively.</p>
</caption>
<graphic xlink:href="fbioe-09-761518-g006.tif"/>
</fig>
<p>The histopathological changes of the mouse footpads in different groups were further analyzed on Day 18 and 26 (<xref ref-type="fig" rid="F6">Figure&#x20;6C</xref>). On Day 18, suppurative granulomas with numerous neutrophils and lymphocytes were observed in the infection group, while the inflammation was significantly less in the laser and laser &#x2b; ToAP2D groups. On Day 26, though inflammation still existed in the infection and laser group, the number of inflammatory cells in the laser group was significantly lower than those in the infection group. In comparison, the mouse histopathology in the laser &#x2b; ToAP2D group almost returned to normal, in which the pus-like inflammatory focus was almost disappeared. In addition, quantitative analysis was performed to evaluate the percentage of inflammatory cells on Day 18 and 26. The laser &#x2b; ToAP2D group showed the greatest decrease in the area containing inflammatory cells, while a large number of inflammatory cells still existed in the infected group on Day 26 (<xref ref-type="fig" rid="F6">Figure&#x20;6D</xref>). Taken together, we demonstrated that ToAP2D promoted mouse footpads recovery, which may be used as an alternative for clinical <italic>S. globosa</italic> treatment.</p>
<p>
<italic>In vitro</italic> study, we have shown that antibacterial peptide ToAP2D can promote <italic>S. globosa</italic> apoptosis through dysfunctional mitochondria, ROS accumulation, and metacaspase activation. Caspase-3 is a critical executioner of apoptosis (<ext-link ext-link-type="uri" xlink:href="https://www.geenmedical.com/article?id=12079293&amp;type=true">apotosis-related proteins in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix</ext-link>). <italic>In vivo</italic> study, we further measured the expression of caspase-3 of mice food pad tissues in different groups. Compared with the HC group (0.50&#x20;&#xb1; 0.08), our data showed that caspase-3 levels were upregulated in the laser &#x2b; ToAP2D group on Day 18 (0.63&#x20;&#xb1; 0.12; <italic>p</italic>&#x20;&#x3d; 0.044) and 26 (0.66&#x20;&#xb1; 0.11; <italic>p</italic>&#x20;&#x3d; 0.013), whereas no significant difference was found in the infection and laser groups, indicating that apoptosis was also activated by ToAP2D treatment <italic>in vivo</italic> (<xref ref-type="fig" rid="F6">Figures&#x20;6E,F</xref>).</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>In this study, we developed three ToAP2 derived peptides with antimicrobial activities. Among them, ToAP2D has the best anti-<italic>S. globosa</italic> efficacy, and its serum stability was good without acute toxicity. ToAP2D showed a robust therapeutic effect on <italic>S. globosa</italic>. ToAP2D inhibited the growth of <italic>S. globosa</italic>. Meanwhile, it also triggered apoptotic pathway in <italic>S. globosa</italic>, including dysfunctional mitochondria, ROS accumulation, and metacaspase activation. In the <italic>in vivo</italic> study, we further demonstrated that ToAP2D inhibited <italic>S. globosa</italic> infection in mice footpads, and the efficacy was nearly equal to that of itraconazole. Moreover, ToAP2D treatment upregulated apoptosis-related protein caspase-3. Collectively, our antimicrobial peptide ToAP2 can inhibit the growth of <italic>S. globosa</italic> and trigger its apoptosis, which may be a potential drug for future sporotrichosis treatment.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by the Ethics Committee of experimental animals, School of basic medicine, Jilin University.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>FC and JL designed and conceived the study. TY and FL performed the experiments and data analysis. All authors participated in writing the article and approved it for publication.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This study was supported partially by grants from the Chinese National Natural Sciences Foundation (82003368), Jilin Provincial Development and Reform Commission Project, China (2020c053), and Projects of Jilin Province Science and Technology Development Plan (20180414033GH).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fbioe.2021.761518/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fbioe.2021.761518/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image3.TIF" id="SM1" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image4.TIF" id="SM2" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.TIF" id="SM3" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.TIF" id="SM4" mimetype="application/TIF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.docx" id="SM5" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbotsford</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Goff</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Blyth</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Yeoh</surname>
<given-names>D. K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Clinical Experience with SUBA-Itraconazole at a Tertiary Paediatric Hospital</article-title>. <source>J.&#x20;Antimicrob. Chemother.</source> <volume>76</volume> (<issue>1</issue>), <fpage>249</fpage>&#x2013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkaa382</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Artzi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sprecher</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mehrabi</surname>
<given-names>J.&#x20;N.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hilerowich</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Fractional Ablative CO2 Laser Followed by Topical Application of Sodium Stibogluconate for Treatment of Active Cutaneous Leishmaniasis: A Randomized Controlled Trial</article-title>. <source>Acta Derm Venereol.</source> <volume>99</volume> (<issue>1</issue>), <fpage>53</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.2340/00015555-3058</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batista-Duharte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>T&#xe9;llez-Mart&#xed;nez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Roberto de Andrade</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Portuondo</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Jellmayer</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Polesi</surname>
<given-names>M. C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Sporothrix Brasiliensis Induces a More Severe Disease Associated with Sustained Th17 and Regulatory T&#x20;Cells Responses Than Sporothrix Schenckii Sensu Stricto in Mice</article-title>. <source>Fungal Biol.</source> <volume>122</volume> (<issue>12</issue>), <fpage>1163</fpage>&#x2013;<lpage>1170</lpage>. <pub-id pub-id-type="doi">10.1016/j.funbio.2018.08.004</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chakrabarti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonifaz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gutierrez-Galhardo</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Mochizuki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Global Epidemiology of Sporotrichosis</article-title>. <source>Med. Mycol.</source> <volume>53</volume> (<issue>1</issue>), <fpage>3</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1093/mmy/myu062</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>C.-K.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>M.-C.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>C.-Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Antimicrobial Activity of the Peptide LfcinB15 against Candida Albicans</article-title>. <source>JoF</source> <volume>7</volume> (<issue>7</issue>), <fpage>519</fpage>. <pub-id pub-id-type="doi">10.3390/jof7070519</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D. G.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Oxidative Stress by Antimicrobial Peptide Pleurocidin Triggers Apoptosis in Candida Albicans</article-title>. <source>Biochimie</source> <volume>93</volume> (<issue>10</issue>), <fpage>1873</fpage>&#x2013;<lpage>1879</lpage>. <pub-id pub-id-type="doi">10.1016/j.biochi.2011.07.011</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coleman</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>M. F.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Rho GTPase Signalling Pathways in the Morphological Changes Associated with Apoptosis</article-title>. <source>Cell Death Differ</source> <volume>9</volume> (<issue>5</issue>), <fpage>493</fpage>&#x2013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4400987</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deslouches</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>Y. P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Antimicrobial Peptides with Selective Antitumor Mechanisms: prospect for Anticancer Applications</article-title>. <source>Oncotarget</source> <volume>8</volume> (<issue>28</issue>), <fpage>46635</fpage>&#x2013;<lpage>46651</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.16743</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etchecopaz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Toscanini</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Gisbert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scarpa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iovannitti</surname>
<given-names>C. A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Sporothrix Brasiliensis: A Review of an Emerging South American Fungal Pathogen, its Related Disease, Presentation and Spread in Argentina</article-title>. <source>JoF</source> <volume>7</volume> (<issue>3</issue>), <fpage>170</fpage>. <pub-id pub-id-type="doi">10.3390/jof7030170</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garc&#xed;a Lozano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Toriello</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Antonio-Herrera</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bonifaz</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Sporothrix Schenckii Immunization, but Not Infection, Induces Protective Th17 Responses Mediated by Circulating Memory CD4&#x2b; T&#x20;Cells</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <fpage>1275</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.01275</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garc&#xed;a Carnero</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Lozoya P&#xe9;rez</surname>
<given-names>N. E.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez Hern&#xe1;ndez</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Mart&#xed;nez &#xc1;lvarez</surname>
<given-names>J.&#x20;&#xc1;.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Immunity and Treatment of Sporotrichosis</article-title>. <source>J.&#x20;Fungi (Basel).</source> <volume>4</volume> (<issue>3</issue>), <fpage>100</fpage>. <pub-id pub-id-type="doi">10.3390/jof4030100</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guaragnella</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>&#x17d;dralevi&#x107;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Antonacci</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Passarella</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marra</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Giannattasio</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The Role of Mitochondria in Yeast Programmed Cell Death</article-title>. <source>Front. Oncol.</source> <volume>2</volume>, <fpage>70</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2012.00070</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guilhelmelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vilela</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Albuquerque</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Derengowski</surname>
<given-names>L. d. S.</given-names>
</name>
<name>
<surname>Silva-Pereira</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kyaw</surname>
<given-names>C. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Antibiotic Development Challenges: the Various Mechanisms of Action of Antimicrobial Peptides and of Bacterial Resistance</article-title>. <source>Front. Microbiol.</source> <volume>4</volume>, <fpage>353</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2013.00353</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guilhelmelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vilela</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Smidt</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>da Cunha Morales &#xc1;lvares</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rigonatto</surname>
<given-names>M. C. L.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Activity of Scorpion Venom-Derived Antifungal Peptides against Planktonic Cells of Candida Spp. And Cryptococcus Neoformans and Candida Albicans Biofilms</article-title>. <source>Front. Microbiol.</source> <volume>7</volume>, <fpage>1844</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2016.01844</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Honse</surname>
<given-names>C. O.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Gremi&#xe3;o</surname>
<given-names>I. D. F.</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Schubach</surname>
<given-names>T. M. P.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Use of Local Hyperthermia to Treat Sporotrichosis in a Cat</article-title>. <source>Vet. Rec.</source> <volume>166</volume> (<issue>7</issue>), <fpage>208</fpage>&#x2013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1136/vr.b4768</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shiozaki</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Yeast Signaling Pathways in the Oxidative Stress Response</article-title>. <source>Mutat. Res.</source> <volume>569</volume> (<issue>1-2</issue>), <fpage>13</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2004.09.006</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayawant</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Hutchinson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gaspar&#xed;kov&#xe1;</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lockey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pru&#xf1;onosa Lara</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guy</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Molecular Basis of Selectivity and Activity for the Antimicrobial Peptide Lynronne&#x2010;1 Informs Rational Design of Peptide with Improved Activity</article-title>. <source>ChemBioChem</source> <volume>22</volume>, <fpage>2430</fpage>&#x2013;<lpage>2439</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.202100151</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Antimicrobial Peptide Brevinin-1RL1 from Frog Skin Secretion Induces Apoptosis and Necrosis of Tumor Cells</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>7</issue>), <fpage>2059</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26072059</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>M. I.</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.-o.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y.-H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Identification of Brevinin-1EMa-Derived Stapled Peptides as Broad-Spectrum Virus Entry Blockers</article-title>. <source>Virology</source> <volume>561</volume>, <fpage>6</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2021.05.004</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Possible Mechanisms of the Antimicrobial Effects of Polypeptide-enriched Gastrodia E-lata Blume E-xtracts</article-title>. <source>Mol. Med. Rep.</source> <volume>20</volume> (<issue>5</issue>), <fpage>4723</fpage>&#x2013;<lpage>4730</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2019.10706</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreling</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Aida</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Massunari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Caiaffa</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Percinoto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bedran</surname>
<given-names>T. B. L.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Cytotoxicity and the Effect of Cationic Peptide Fragments against Cariogenic Bacteria under Planktonic and Biofilm Conditions</article-title>. <source>Biofouling</source> <volume>32</volume> (<issue>9</issue>), <fpage>995</fpage>&#x2013;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1080/08927014.2016.1218850</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Celastrol Self-Stabilized Nanoparticles for Effective Treatment of Melanoma</article-title>. <source>Ijn</source> <volume>Vol. 15</volume>, <fpage>1205</fpage>&#x2013;<lpage>1214</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s232603</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lima</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>J.&#x20;T.</given-names>
</name>
<name>
<surname>Amaral</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>P. F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Synthetic Antimicrobial Peptides: Characteristics, Design, and Potential as Alternative Molecules to Overcome Microbial Resistance</article-title>. <source>Life Sci.</source> <volume>278</volume>, <fpage>119647</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2021.119647</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>M F Matos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>M Moreira</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>F Barczewski</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>X de Matos</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>B V de Oliveira</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>F Pimentel</surname>
<given-names>M. I.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Identification by MALDI-TOF MS of Sporothrix Brasiliensis Isolated from a Subconjunctival Infiltrative Lesion in an Immunocompetent Patient</article-title>. <source>Microorganisms</source> <volume>8</volume> (<issue>1</issue>), <fpage>22</fpage>. <pub-id pub-id-type="doi">10.3390/microorganisms8010022</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madeo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carmona-Gutierrez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ring</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>B&#xfc;ttner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eisenberg</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Caspase-dependent and Caspase-independent Cell Death Pathways in Yeast</article-title>. <source>Biochem. biophysical Res. Commun.</source> <volume>382</volume> (<issue>2</issue>), <fpage>227</fpage>&#x2013;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2009.02.117</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mwangi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The Antimicrobial Peptide ZY4 Combats Multidrug-resistantPseudomonas aeruginosaandAcinetobacter Baumanniiinfection</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>116</volume> (<issue>52</issue>), <fpage>26516</fpage>&#x2013;<lpage>26522</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1909585117</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orringer</surname>
<given-names>J.&#x20;S.</given-names>
</name>
<name>
<surname>Ritti&#xe9;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Voorhees</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Molecular Mechanisms of Nonablative Fractionated Laser Resurfacing</article-title>. <source>Br. J.&#x20;Dermatol.</source> <volume>163</volume> (<issue>4</issue>), <fpage>757</fpage>&#x2013;<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2010.09998.x</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Kuerban</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>S-ethyl Ethanethiosulfinate, a Derivative of Allicin, Induces Metacaspase-dependent Apoptosis through ROS Generation in Penicillium chrysogenum</article-title>. <source>Biosci. Rep.</source> <volume>39</volume> (<issue>6</issue>), <fpage>BSR20190167</fpage>. <pub-id pub-id-type="doi">10.1042/BSR20190167</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riwaldt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Corydon</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Pantalone</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sahana</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wise</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wehland</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Role of Apoptosis in Wound Healing and Apoptosis Alterations in Microgravity</article-title>. <source>Front. Bioeng. Biotechnol.</source> <volume>9</volume>, <fpage>498</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2021.679650</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubin</surname>
<given-names>S. J.&#x20;S.</given-names>
</name>
<name>
<surname>Qvit</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Engineering "Antimicrobial Peptides" and Other Peptides to Modulate Protein-Protein Interactions in Cancer</article-title>. <source>Ctmc</source> <volume>20</volume> (<issue>32</issue>), <fpage>2970</fpage>&#x2013;<lpage>2983</lpage>. <pub-id pub-id-type="doi">10.2174/1568026620666201021141401</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabi&#xe1; J&#xfa;nior</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>L. F. S.</given-names>
</name>
<name>
<surname>de Ara&#xfa;jo</surname>
<given-names>I. F. S.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>E. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Natural Occurrence in Venomous Arthropods of Antimicrobial Peptides Active against Protozoan Parasites</article-title>. <source>Toxins</source> <volume>11</volume> (<issue>10</issue>), <fpage>563</fpage>. <pub-id pub-id-type="doi">10.3390/toxins11100563</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Saikumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kar</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2008</year>). &#x201c;<article-title>Apoptosis and Cell Death: Relevance to Lung</article-title>,&#x201d; in <source>Molecular Pathology of Lung Diseases</source> (<publisher-name>Springer</publisher-name>), <fpage>40</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-72430-0_4</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schafer</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Browne</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>J.&#x20;B.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>D. E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Peptides and Antibiotic Therapy: Advances in Design and Delivery</article-title>. <source>Acc. Chem. Res.</source> <volume>54</volume> (<issue>10</issue>), <fpage>2377</fpage>&#x2013;<lpage>2385</lpage>. <pub-id pub-id-type="doi">10.1021/acs.accounts.1c00040</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobhi</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Adawy</surname>
<given-names>N. A. H.</given-names>
</name>
<name>
<surname>Zaky</surname>
<given-names>I. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Comparative Study between the Efficacy of Fractional CO2 Laser, Q-Switched Nd:YAG Laser (1064&#xa0;nm), and Both Types in Treatment of Keratosis Pilaris</article-title>. <source>Lasers Med. Sci.</source> <volume>35</volume>, <fpage>1367</fpage>&#x2013;<lpage>1376</lpage>. <pub-id pub-id-type="doi">10.1007/s10103-020-02956-w</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soeiro Sampaio</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Sguissardi de Oliveira</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Saraiva Freitas</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Francesconi do Valle</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Electrosurgery as Adjuvant Therapy for Cutaneous Sporotrichosis</article-title>. <source>Dermatol. Surg.</source> <volume>46</volume> (<issue>1</issue>), <fpage>140</fpage>&#x2013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1097/dss.0000000000001746</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stariha</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>McCafferty</surname>
<given-names>D. G.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Discovery of the Class I Antimicrobial Lasso Peptide Arcumycin</article-title>. <source>Chembiochem</source> <volume>22</volume>, <fpage>2632</fpage>&#x2013;<lpage>2640</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.202100132</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Struyfs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cammue</surname>
<given-names>B. P. A.</given-names>
</name>
<name>
<surname>Thevissen</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Membrane-Interacting Antifungal Peptides</article-title>. <source>Front. Cel Dev. Biol.</source> <volume>9</volume>, <fpage>649875</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.649875</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Struyfs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cammue</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Thevissen</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021b</year>). <article-title>Membrane-Interacting Antifungal Peptides</article-title>. <source>Front. Cel. Dev. Biol.</source> <volume>9</volume>, <fpage>706</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.649875</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Furio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mecheri</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>van der Does</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Lundeberg</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Saveanu</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Pancreatic &#x3b2;-Cells Limit Autoimmune Diabetes via an Immunoregulatory Antimicrobial Peptide Expressed under the Influence of the Gut Microbiota</article-title>. <source>Immunity</source> <volume>43</volume> (<issue>2</issue>), <fpage>304</fpage>&#x2013;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.07.013</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira Bard</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>V. V.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>A. E. A.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Da Cunha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>G. B.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Vicilin-like Peptides fromCapsicum baccatumL. Seeds Are &#x3b1;-amylase Inhibitors and Exhibit Antifungal Activity against Important Yeasts in Medical Mycology</article-title>. <source>Biopolymers</source> <volume>102</volume> (<issue>4</issue>), <fpage>335</fpage>&#x2013;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1002/bip.22504</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wassing</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lindbom</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>van der Does</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Complexity of Antimicrobial Peptide Regulation during Pathogen-Host Interactions</article-title>. <source>Int. J.&#x20;Antimicrob. Agents</source> <volume>45</volume> (<issue>5</issue>), <fpage>447</fpage>&#x2013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.11.003</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenande</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Olesen</surname>
<given-names>U. H.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M. M. B.</given-names>
</name>
<name>
<surname>Janfelt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>R. R.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Fractional Laser-Assisted Topical Delivery Leads to Enhanced, Accelerated and Deeper Cutaneous 5-fluorouracil Uptake</article-title>. <source>Expert Opin. Drug Deliv.</source> <volume>14</volume> (<issue>3</issue>), <fpage>307</fpage>&#x2013;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1080/17425247.2017.1260119</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Inhibitory Effect of a Novel Chicken-Derived Anti-biofilm Peptide on <italic>P. aeruginosa</italic> Biofilms and Virulence Factors</article-title>. <source>Microb. Pathogenesis</source> <volume>149</volume>, <fpage>104514</fpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2020.104514</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.&#x20;f.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Epidemiological and Clinical Comparisons of Paediatric and Adult Sporotrichosis in Jilin Province, China</article-title>. <source>Mycoses</source> <volume>63</volume> (<issue>3</issue>), <fpage>308</fpage>&#x2013;<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1111/myc.13045</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A Conformally Adapted All-In-One Hydrogel Coating: towards Robust Hemocompatibility and Bactericidal Activity</article-title>. <source>J.&#x20;Mater. Chem. B</source> <volume>9</volume> (<issue>11</issue>), <fpage>2697</fpage>&#x2013;<lpage>2708</lpage>. <pub-id pub-id-type="doi">10.1039/d1tb00021g</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>